Drug Initiative

Is the FDA ignoring heart risks from high triglycerides in the face of mounting evidence to the contrary?

The lives of millions of Americans are potentially at risk.

The EPA Drug Initiative (EPADI) urges the FDA to thoughtfully consider new and almost irrefutable proof that high triglycerides are a significant risk factor contributing to cardiovascular disease-related death and morbidity.

Recently, two independent studies were published in the prestigious New England Journal of Medicine (NEJM), both drawing the same conclusion: that reducing serum triglycerides to accepted, safe levels resulted in a 40% decrease in cardiovascular risk. These trial results are being universally hailed as groundbreaking, as they focus on people having a certain gene mutation, which elegantly eliminates all cardiovascular disease risk factors other than serum triglyceride levels. Both studies—from well-respected researchers—have caught the attention of the world, with the results being published by prominent news media including the New York Times and Forbes.

Read the Full Story

I started on Vascepa 8 months ago for elevated lipids..I take 4gms a day..The medication produces no GI problems such as reflux..Seems to have a mild antidepressive effect, and in addition to improving my lipid profiles also did something truly remarkable in that it cleared up my dry eye problems so much so that I have not needed eye drops for the past seven months, where as before I was using them every half hour..


Anthony W.
Back To Top